Cargando…
Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
Immune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, man...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512939/ https://www.ncbi.nlm.nih.gov/pubmed/37744323 http://dx.doi.org/10.3389/fimmu.2023.1236965 |